Lucid Diagnostics Announces Closing of Public Offering of Common Stock
Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company and PAVmed Inc. subsidiary, has completed its previously announced underwritten public offering. The company successfully raised $16.1 million in net proceeds through the sale of 14,375,000 shares of common stock at $1.20 per share, which included 1,875,000 shares from the underwriters' option exercise.
The offering was conducted under a shelf registration statement, with Canaccord Genuity serving as the sole bookrunner and Maxim Group as co-manager. The company plans to utilize the proceeds for working capital and general corporate purposes.
Lucid Diagnostics (Nasdaq: LUCD), un'azienda di diagnostica medica per la prevenzione del cancro in fase commerciale e sussidiaria di PAVmed Inc., ha completato l'offerta pubblica sottoscritta precedentemente annunciata. L'azienda ha raccolto con successo 16,1 milioni di dollari in proventi netti attraverso la vendita di 14.375.000 azioni di azioni ordinarie a 1,20 dollari per azione, che includevano 1.875.000 azioni dall'esercizio dell'opzione degli underwriter.
L'offerta è stata condotta sotto una dichiarazione di registrazione a scaffale, con Canaccord Genuity come unico bookrunner e Maxim Group come co-manager. L'azienda prevede di utilizzare i proventi per il capitale circolante e scopi aziendali generali.
Lucid Diagnostics (Nasdaq: LUCD), una empresa de diagnóstico médico en etapa comercial para la prevención del cáncer y subsidiaria de PAVmed Inc., ha completado su oferta pública suscrita previamente anunciada. La compañía recaudó con éxito 16.1 millones de dólares en ingresos netos a través de la venta de 14,375,000 acciones de acciones ordinarias a 1.20 dólares por acción, que incluía 1,875,000 acciones del ejercicio de la opción de los suscriptores.
La oferta se llevó a cabo bajo una declaración de registro en estante, con Canaccord Genuity como único bookrunner y Maxim Group como co-administrador. La compañía planea utilizar los ingresos para capital de trabajo y propósitos corporativos generales.
Lucid Diagnostics (Nasdaq: LUCD), 상업 단계의 암 예방 의료 진단 회사이자 PAVmed Inc.의 자회사, 가 이전에 발표한 공모 청약을 완료했습니다. 이 회사는 1,610만 달러의 순수익을 14,375,000주의 보통주를 주당 1.20달러에 판매하여 성공적으로 모금했습니다. 여기에는 인수자 옵션 행사로부터의 1,875,000주가 포함됩니다.
이번 공모는 선반 등록 성명서에 따라 진행되었으며, Canaccord Genuity가 단독 북런너로, Maxim Group이 공동 관리자 역할을 했습니다. 이 회사는 수익을 운영 자본 및 일반 기업 목적에 사용할 계획입니다.
Lucid Diagnostics (Nasdaq: LUCD), une entreprise de diagnostics médicaux en phase commerciale pour la prévention du cancer et filiale de PAVmed Inc., a complété son offre publique souscrite précédemment annoncée. L'entreprise a réussi à lever 16,1 millions de dollars en produits nets grâce à la vente de 14.375.000 actions ordinaires à 1,20 dollar par action, ce qui incluait 1.875.000 actions issues de l'exercice de l'option des souscripteurs.
L'offre a été réalisée sous une déclaration d'enregistrement de type shelf, avec Canaccord Genuity comme unique bookrunner et Maxim Group comme co-gestionnaire. L'entreprise prévoit d'utiliser les produits pour le fonds de roulement et des fins corporatives générales.
Lucid Diagnostics (Nasdaq: LUCD), ein Unternehmen für medizinische Diagnostik zur Krebsprävention in der kommerziellen Phase und Tochtergesellschaft von PAVmed Inc., hat das zuvor angekündigte öffentliche Angebot erfolgreich abgeschlossen. Das Unternehmen hat 16,1 Millionen Dollar an Nettomitteln durch den Verkauf von 14.375.000 Aktien zu einem Preis von 1,20 Dollar pro Aktie erfolgreich gesammelt, einschließlich 1.875.000 Aktien aus der Ausübung der Option der Underwriter.
Das Angebot wurde unter einer Shelf-Registrierungserklärung durchgeführt, wobei Canaccord Genuity als alleiniger Bookrunner und Maxim Group als Co-Manager fungierte. Das Unternehmen plant, die Erlöse für Betriebskapital und allgemeine Unternehmenszwecke zu verwenden.
- Successfully raised $16.1 million in new capital
- Full exercise of underwriters' option indicates strong demand
- Potential dilution for existing shareholders
- Offering price of $1.20 per share may indicate challenging market conditions
Insights
Lucid Diagnostics has completed a public offering of 14,375,000 shares at
The
For a commercial-stage diagnostics company, securing this capital strengthens Lucid's financial position, providing runway for their cancer prevention diagnostic commercialization efforts. However, the stated use of proceeds as "working capital and general corporate purposes" offers insight into specific strategic initiatives.
This capital raise represents a double-edged sword for investors - the dilution immediately reduces per-share ownership, but the additional funding reduces near-term financing risk. Without specific information on Lucid's current cash position or burn rate, it's difficult to determine how long this additional capital will extend the company's operations. For LUCD to create long-term shareholder value, management must efficiently deploy this capital toward achieving commercial milestones that outweigh the dilution impact.
The total net proceeds from the offering, after deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately
Canaccord Genuity LLC acted as the sole bookrunner of the offering, and Maxim Group LLC acted as co-manager.
The securities were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-268560) declared effective by the Securities and Exchange Commission on December 6, 2022. A prospectus supplement relating to the offering was filed with the Securities and Exchange Commission, together with an accompanying base prospectus, on April 10, 2025. Copies of the prospectus supplement relating to the offering, together with the accompanying base prospectus, may be obtained from Canaccord Genuity LLC, Attention: Syndicate Department, One Post Office Square, Suite 3000,
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information about Lucid, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.
Forward-Looking Statements
This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of Lucid Diagnostics' management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of Lucid Diagnostics' common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance Lucid Diagnostics' products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from Lucid Diagnostics' clinical and preclinical studies; whether and when Lucid Diagnostics' products are cleared by regulatory authorities; market acceptance of Lucid Diagnostics' products once cleared and commercialized; Lucid Diagnostics' ability to raise additional funding as needed; and other competitive developments. These factors are difficult or impossible to predict accurately and many of them are beyond Lucid Diagnostics' control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect Lucid Diagnostics' future operations, see Part I, Item 1A, "Risk Factors," in Lucid Diagnostics' most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its most recent Annual Report. Lucid Diagnostics disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-announces-closing-of-public-offering-of-common-stock-302426586.html
SOURCE Lucid Diagnostics
FAQ
How much did Lucid Diagnostics (LUCD) raise in its April 2025 public offering?
What was the share price and total number of shares in LUCD's 2025 public offering?
How will Lucid Diagnostics use the proceeds from its 2025 stock offering?
Who were the underwriters for Lucid Diagnostics' April 2025 public offering?
